Q-omics provides the consensus-scored BORCS7-ASMT profile across patient tissues and cancer cell-line models. BORCS7-ASMT expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, BORCS7-ASMT is differentially expressed in 1, with the highest sampling consensus in PAAD. Additionally, BORCS7-ASMT RNA expression shows 2,946 significant gene co-expression associations, with the highest sampling consensus in UCS. Together, these results highlight MESO, PAAD, and UCS as cancer lineages where BORCS7-ASMT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BORCS7-ASMT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BORCS7-ASMT survival associations across molecular data types. BORCS7-ASMT RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BORCS7-ASMT RNA expression–survival associations across cancer types. High BORCS7-ASMT expression shows unfavorable associations in MESO, ESCA, UVM, SARC, THYM and BLCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for BORCS7-ASMT RNA expression.
This table summarizes BORCS7-ASMT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PAAD for RNA.
This table ranks reproducible tumor–normal expression differences for BORCS7-ASMT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BORCS7-ASMT shows lower tumor expression in PAAD. The PAAD box plot shows higher BORCS7-ASMT RNA expression in normal versus tumor tissue (log2 FC = −0.035, t-test p = .019).
This table shows molecular features associated with BORCS7-ASMT in patient tissues and cancer cell lines. In patient samples, BORCS7-ASMT shows the broadest associations at the RNA and protein expression levels, with UCS recurring as the lineage with the largest associated feature set. In cancer cell lines, BORCS7-ASMT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
